[THE INVESTOR] Samsung Bioepis said on Jan. 7 it is entering the Chinese market through a biosimilar commercialization partnership with 3SBio.
This will be the third overseas destination for the drug development arm of Samsung Group, following Europe and the US.
The licensing agreement covers multiple biosimilar candidates, including sB8 that references Avastin. With this partnership, the firm will receive support related to clinical development, regulatory registration and commercialization in China. The company did not disclose any financial details of the agreement.
“The alliance will bring together our proven development platform and 3SBio’s strong commercialization platform,” said Samsung Bioepis President and CEO Ko Han-sung.
“We hope to see our biosimilars play an important role in widening patient access to high-quality health care.”
3SBio is a Chinese biotech company with manufacturing capabilities focusing on recombinant proteins, monoclonal antibodies and chemically synthesized molecules. It currently has over 30 drug candidates under development.
By Choi Ji-won (firstname.lastname@example.org)